The FDA’s Vaccines and Related Biological Products Advisory Committee urged manufacturers to remove the influenza B Yamagata lineage strain from next season’s flu shots during a March 5 meeting. The flu type B lineage hasn’t been detected globally since March 2020 and no longer poses a threat to public health, the committee said.
The move marks a return to trivalent vaccines after more than a decade — the FDA approved the first quadrivalent flu vaccine that includes the second type B strain in 2012.
The FDA said it’s working with manufacturers to have “an adequate and diverse supply” of trivalent flu shots ready for next flu season.
Learn more here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.